ArticlePLOS global public health2026
Impact of Universal Test and Treat (UTT) on anticipated stigma among patients newly diagnosed with HIV in Johannesburg, South Africa: A cross-sectional study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticipated stigma-the fear that an HIV diagnosis and disclosure may lead to negative social consequences that undermine engagement in HIV care, even in the era of universal test-and-treat (UTT). This study aimed to estimate the prevalence of anticipated stigma and identify its predictors among newly HIV-diagnosed adults in Johannesburg, South Africa, where treatment is available. We conducted a cross-sectional survey among 652 adults (≥18 years) newly diagnosed with HIV between October 2017 and August 2018 at four primary healthcare clinics in Johannesburg. Participants (64.1% female; median age 33 years, IQR 28-39) were interviewed immediately after receiving their HIV test results. Anticipated stigma was measured using an adapted five-item, four-point scale assessing concerns related to HIV disclosure and concealment (Cronbach's alpha = 0.82). Mean scores were categorized as low-to-medium (≤2.5) or high (>2.5). Modified Poisson regression was used to identify predictors of high anticipated stigma, reported as adjusted risk ratios (aRRs) with 95% confidence intervals (CIs). Overall, 55% of participants reported high anticipated stigma. Prevalence was higher among males (55.8%) and young adults aged 18-29 years (61.1%), and lower among married individuals (43%). Compared to married participants, those in unmarried relationships were more likely to report high anticipated stigma (aRR 1.10, 95% CI: 1.01-1.18). Lower anticipated stigma was observed among older individuals (aRR 0.94 for ages 30-39 vs 18-29), those whose primary home was in another province or country, those living in their current home for five or more years, individuals with fewer ART-related concerns, and those reporting lower perceived social support. Despite universal access to HIV treatment, over half of newly diagnosed adults reported high anticipated stigma. These findings underscore the need for targeted interventions to address persistent drivers of stigma, strengthen coping skills, and support social integration to promote engagement in HIV care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.